1. A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma. (23rd June 2021) Authors: Monteith, Bethany E.; Venner, Christopher P.; Cheung, Matthew C.; Pater, Joe; Shepherd, Lois; Richardson, Harriet; Reece, Donna; Gul, Engin; Lalancette, Marc; Castonguay, Vincent; Kukreti, Vishal; Tiedemann, Rodger; Phua, Chai; Bhella, Sita; Dudebout, Jill; Sherry, Max; Yen, Hope; Chen, Bingshu E... Journal: European journal of haematology Issue: Volume 107:Number 3(2021) Page Start: 333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era. (October 2018) Authors: Savoie, Mary Lynn; Bence-Bruckler, Isabelle; Huebsch, Lothar B.; Lalancette, Marc; Hillis, Chris; Walker, Irwin; Lipton, Jeffrey H.; Forrest, Donna L.; Kim, Dennis (Dong Hwan) Journal: Leukemia research Issue: Volume 73(2018) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN‐003/MYX.1 single arm phase II trial. Issue 5 (12th April 2021) Authors: Venner, Christopher P.; LeBlanc, Richard; Sandhu, Irwindeep; White, Darrell; Belch, Andrew R.; Reece, Donna E.; Chen, Christine; Dolan, Sean; Lalancette, Marc; Louzada, Martha; Kew, Andrea; McCurdy, Arleigh; Monteith, Bethany; Reiman, Tony; McDonald, Gail; Sherry, Max; Gul, Engin; Chen, Bingshu E... Journal: American journal of hematology Issue: Volume 96:Issue 5(2021) Page Start: 552 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗